Kura Oncology to Present Updated Darlifarnib Combination Data for Renal Cell Carcinoma at IKCS Europe 2026
Key Insights
Kura Oncology will present updated data from the FIT-001 clinical trial evaluating darlifarnib (search) plus cabozantinib in advanced clear cell renal cell carcinoma (search) patients at IKCS Europe 2026.
The combination demonstrated encouraging clinical activity and manageable safety profile in earlier findings presented at ESMO 2025 Congress.
Darlifarnib (search) is designed to overcome resistance and resensitize tumors to VEGFR (search) TKI therapy through its mechanism of inhibiting farnesylation of RHEB (search) and suppressing mTORC1 (search) signaling.
Kura Oncology announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (search) (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (search) at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France.
The data build on earlier findings from the FIT-001 study reported at the 2025 European Society for Medical Oncology (ESMO) Congress, where the combination of darlifarnib (search) and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile in patients with advanced renal cell carcinoma (search).
Clinical Trial Design and Patient Population
The presentation will focus on preliminary Phase 1 results from patients with clear cell renal cell carcinoma (search) who had prior exposure to cabozantinib. The study represents a novel approach to addressing treatment resistance in this patient population by combining a farnesyl transferase inhibitor with an established VEGFR (search)-targeted therapy.
Mechanism of Action and Therapeutic Rationale
Darlifarnib (search) is a next-generation farnesyl transferase inhibitor (FTI) designed to inhibit farnesylation of RHEB (search) and suppress mTORC1 (search) signaling. This mechanism has potential to enhance the activity of multiple targeted therapies, including VEGFR (search)-targeted therapies such as cabozantinib. The approach aims to overcome resistance and resensitize tumors to VEGFR TKI therapy.
Conference Presentation Details
The presentation, titled "Farnesyl transferase inhibitor (FTI) darlifarnib (search) (KO-2806) combined with cabozantinib (cabo) in clear cell renal cell carcinoma (search) (ccRCC) patients after prior exposure to cabo: Preliminary Phase 1 results from FIT-001," is scheduled for Abstract Session 7 on April 17, 2026, from 3:30 p.m. to 4:30 p.m. CEST.
Kura will also host a virtual investor webcast and conference call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST, featuring management and a clinical investigator from the darlifarnib (search) program.
Company Background
Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment. The company's pipeline of small molecule drug candidates targets cancer signaling pathways and addresses high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin (search) inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (search).